Premium
Perioperative Administration of Statins has Cardioprotective Effects in Streptozotocin‐induced Diabetic Rats
Author(s) -
Crespo Maria J.,
Cruz Nildris,
Quidgley Jose,
Creagh Osmar,
Torres Hector,
Rivera Karines,
Hernandez Cesar
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1057.20
Subject(s) - medicine , perioperative , pravastatin , ejection fraction , atorvastatin , diabetes mellitus , cardiac function curve , simvastatin , cardioprotection , cardiology , streptozotocin , anesthesia , urology , myocardial infarction , endocrinology , cholesterol , heart failure
Cardiovascular (CV) function improves postoperative outcomes for patients receiving statins in the perioperative period. The optimal time for administering statins to obtain cardioprotective effects during this period in diabetes is unknown. Using echocardiography, we compared the effects of 24‐hour vs. one‐week administration of simvastatin (SV, 10 mg/kg/d); pravastatin (PV, 10 mg/kg/d) and atorvastatin (AV, 10 mg/kg/d) on the CV status of STZ‐induced diabetic rats. Untreated diabetic rats were used as controls. 24‐hour treatment increased ejection fraction (AV: 57.67±10.47%; PV: 51±8.44%; SV 65±9.5%), when compared to non‐treated diabetic rats (44±0.1%, N=4, P<0.05). Cardiac output index (COI, ml/min × 100 gBW) (AV: 88.55±29.54; PV: 81.58±29.31; SV: 90.39±18.86), and stroke volume (mL) (AV: 0.63±0.23; PV: 0.58±0.17; SV: 0.60±0.16) were also improved, when compared to non‐treated diabetic rats (COI: 52±15.76; Stroke Volume: 0.31±0.03 mL; N=4, P<0.05). After one‐week administration of AV and SV, cardiac parameters were similar to those observed after 24 hours. In the PV group, by contrast, the beneficial effects were not maintained after one‐week. These results indicate that cardioprotective effects of statins appear as early as 24 hours after administration. This study has strong clinical implications for diabetic patients who are subjected to surgical procedures. MBRS‐RISE Grant R25‐GM061838